FDA Approves Oral Treatment for Myelodysplastic Syndrome
WEDNESDAY, July 8, 2020 -- The U.S. Food and Drug Administration has approved Inqovi (decitabine and cedazuridine) tablets, an oral outpatient treatment option for patients with myelodysplastic syndromes and chronic myelomonocytic leukemia, the agency announced Tuesday.
Inqovi provides another option for patients who previously needed intravenous therapy and will reduce the need for them to frequently visit health care facilities. The tablet is taken once daily for five consecutive days in a 28-day cycle.
The approval was based on data from the ASCERTAIN phase 3 study and supporting phase 1 and 2 clinical studies. Data showed that intravenous decitabine and Inqovi have similar drug concentrations and similar safety profiles. Also, at eight weeks, about half of the patients who had depended on transfusions no longer required transfusions.
Commonly reported side effects of Inqovi include fatigue, constipation, hemorrhage, muscle pain, mucositis, arthralgia, nausea, and fever with low white blood cell count. Inqovi can also cause fetal harm, and those of reproductive age should use effective contraception if taking Inqovi.
Approval was granted to Astex Pharmaceuticals, a subsidiary of Otsuka Pharmaceuticals.
© 2021 HealthDay. All rights reserved.
Posted July 2020
Read this next
TUESDAY, April 6, 2021 -- Angie Gaytan never cared much for beets, but beets sure do love her -- doctors say that veggie shakes, fruits, beet juice and other healthy foods likely...
FRIDAY, April 2, 2021 -- Combining stem cell transplants with cutting-edge immunotherapy prevents leukemia relapses in young people and improves their chances of survival, new...
WEDNESDAY, March 3, 2021 -- A new study provides further evidence that people with certain blood types may be more likely to contract COVID-19. Specifically, it found that the...
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.